Skip to main content Accessibility help
  • Print publication year: 2011
  • Online publication date: December 2011

5 - The epidemiology of multiple sclerosis

from Section I - Introduction


1. Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002; 104:182–91.
2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 1996; 46:907–11.
3. Weinshenker BG, Bass B, Rice PA, et al. The natural history of multiple sclerosis: A geographically based study. 1. Clinical course and disability. Brain 1989; 112:133–46.
4. Compston A, McDonald I, Noseworthy J, et al. McAlpine's Multiple Sclerosis. 4th edn. London: Churchill Livingstone Elsevier, 2006.
5. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurology 2010; 9:520–32.
6. Ness JM, Chabas D, Sadovnick AD, et al. Clinical features of children and adolescents with multiple sclerosis. Neurology 2007; 68:S37–45.
7. Cocco E, Sardu C, Lai M, Spinicci G, Contu P, Marrosu MG. Anticipation of age at onset in multiple sclerosis: a Sardinian cohort study. Neurology 2004; 62:1794–8.
8. Celius EG, Smestad C. Change in sex ratio, disease course and age at diagnosis in Oslo MS patients through seven decades. Acta Neurol Scand 2009; 120:27–9.
9. Barnett MH, Williams DB, Day S, Macaskill P, McLeod JG. Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 35-year study. J Neurol Sci 2003; 213:1–6.
10. Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T. Changes in the ascertainment of multiple sclerosis. Neurology 2005; 65:1066–70.
11. Wolinsky JS, Narayana PA, O’Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61:14–24.
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444–52.
13. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. Neurology 1990; 40:971–5.
14. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: A geographically based study. 2. Predictive value of the early clinical course. Brain 1989; 112:1419–28.
15. Cottrell DA, Kremenchutzky M, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999; 122:625–39.
16. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003; 126:770–82.
17. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343:1430–8.
18. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain 2006; 129:595–605.
19. Pittock SJ, Mayr WT, McClelland RL, et al. Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 2004; 62:601–6.
20. Pittock SJ, Mayr WT, McClelland RL, et al. Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology 2004; 62:51–9.
21. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006; 66:172–7.
22. Tremlett H, Zhao Y, Joseph J, Devonshire V. Relapses in multiple sclerosis are age- and time-dependent. J Neurol, Neurosurg Psychiatry 2008; 79:1368–74.
23. Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of primary progressive multiple sclerosis. Neurology 2009; 73:1996–2002.
24. Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of secondary progressive MS. J Neurol, Neurosurg Psychiatry 2010; 81:1039–43.
25. Tremlett H, Yinshan Zhao, Devonshire V. Natural history of secondary-progressive multiple sclerosis. Mult Scler 2008; 14:314–24.
26. Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology 2005; 65:1919–23.
27. Brown M, Andreou P, Kirby S, Murray J. EDSS natural history atlas: MS disability progression in Nova Scotia 1979–2004. Mult Scler 2008; 14:P540.
28. Brown MG, Kirby S, Skedgel C, et al. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Neurology 2007; 69:1498–507.
29. Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F. Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol 2008; 15:916–21.
30. Debouverie M, Louis S, Pittion-Vouyovitch S, Roederer T, Vespignani H. Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France. J Neurol 2007; 254:1370–5.
31. McLeod JG, Barnett MH, Macaskill P, Williams DB. Long-term prognosis of multiple sclerosis in Australia. J Neurol Sci 2007; 256:35–8.
32. Confavreux C, Compston A. The natural history of Multiple Sclerosis. In: Compston A, McDonald I, Noseworthy J, et al., eds. McAlpine's Multiple Sclerosis. 4th edn. London: Churchill Livingstone Elsevier, 2006.
33. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006; 129:606–16.
34. Broman T, Andersen O, Bergmann L. Clinical studies on multiple sclerosis. I. Presentation of an incidence material from Gothenburg. Acta Neurol Scandinavica 1981; 63:6–33.
35. Patzold U, Pocklington PR. Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976–1980. Acta Neurol Scand 1982; 65:248–66.
36. Goodkin DE, Hertsgaard D, Rudick RA. Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials. Arch Neurol 1989; 46:1107–12.
37. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980; 103:281–300.
38. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008; 7:903–14.
39. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: A geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991; 114:1045–56.
40. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993; 116:117–34.
41. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y, and the UBC Neurologists. The impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009; 17:1616–23.
42. Suissa S. Immortal Time Bias in Pharmacoepidemiology. Am J Epidemiol 2008; 167:492–9.
43. Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007; 356:2603–13.
44. Kremenchutzky M, Rice GPA, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease. Brain 2006; 129:584–94.
45. Langer-Gould A, Popat RA, Huang SM, et al. Clinical and demographic predictors of long-term disability in patients with relapsing–remitting multiple sclerosis: a systematic review. Arch Neurol 2006; 63:1686–91.
46. Argyriou AA, Makris N. Neuromyelitis optica: a distinct demyelinating disease of the central nervous system. Acta Neurol Scand 2008; 118:209–17.
47. Phillips PH, Newman NJ, Lynn MJ. Optic neuritis in African Americans. Arch Neurol 1998; 55:186–92.
48. Weinstock-Guttman B, Jacobs LD, Brownscheidle CM, et al. Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium. Mult Scler 2003; 9:293–8.
49. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Does multiple sclerosis-associated disability differ between races? Neurology 2006; 66:1235–40.
50. Cree BA, Khan O, Bourdette D, et al. Clinical characteristics of African Americans vs. Caucasian Americans with multiple sclerosis. Neurology 2004; 63:2039–45.
51. Cree BA, Al-Sabbagh A, Bennett R, Goodin D. Response to interferon beta-1a treatment in African American multiple sclerosis patients. Arch Neurol 2005; 62:1681–3.
52. Mielke MM, Rosenberg PB, Tschanz J, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology 2007; 69:1850–8.
53. Fernandez HH, Lapane KL. Predictors of mortality among nursing home residents with a diagnosis of Parkinson's disease. Med Sci Monitor 2002; 8:CR241–6.
54. Studenski SA, Lai SM, Duncan PW, Rigler SK. The impact of self-reported cumulative comorbidity on stroke recovery. Age Ageing 2004; 33:195–8.
55. Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity, socioeconomic status, and multiple sclerosis. Mult Scler 2008; 14:1091–8.
56. Warren SA, Turpin KV, Pohar SL, Jones CA, Warren KG. Comorbidity and health-related quality of life in people with multiple sclerosis. Int J MS Care 2009; 11:6–16.
57.Goldman Consensus Group. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler 2005; 11:328–37.
58. Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler 2007; 13:67–72.
59. Niederwieser G, Buchinger W, Bonelli RM, et al. Prevalence of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis. J Neurol 2003; 250:672–5.
60. Barcellos LF, Kamdar BB, Ramsay PP, et al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol 2006; 5:924–31.
61. Sloka JS, Pryse-Phillips WEM, Stefanelli M, Joyce C. Co-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort. J Autoimmune Dis 2005; 2:9.
62. Marrie RA, Horwitz RI, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology 2009; 72:117–24.
63. Rudick RA, Miller DM, Clough JD, Gragg LA, Farmer RG. Quality of life in multiple sclerosis: Comparison with inflammatory bowel disease and rheumatoid arthritis. Arch Neurol 1992; 49:1237–42.
64. Turpin KV, Carroll LJ, Cassidy JD, Hader WJ. Deterioration in the health-related quality of life of persons with multiple sclerosis: the possible warning signs. Mult Scler 2007; 13:1038–45.
65. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005; 129:827–36.
66. Tourbah A, Clapin A, Gout O, et al. Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study. Arch Neurol 1998; 55:517–21.
67. Kirby S, Brown MG, Andreou P, et al. Progression of multiple sclerosis in patients with other autoimmune diseases. Can J Neurol Sci 2009; 36:S-29.
68. Kirby S, Brown MG, Murray TJ, et al. Progression of multiple sclerosis in patients with other autoimmune diseases. Mult Scler 2005; 11:S28–9.
69. Dallmeijer AJ, Beckerman H, de Groot V, van de Port IGL, Lankhorst GJ, Dekker J. Long-term effect of comorbidity on the course of physical functioning in patients after stroke and with multiple sclerosis. J Rehab Med 2009; 41:322–6.
70. Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010; 74:1041–7.
71. Kirby S, Fisk JD, Brown MG, et al. Progression of multiple sclerosis in patients with psychiatric syndromes. Mult Scler 2005; 11:S28–9.
72. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Smoking and lung cancer survival. The role of comorbidity and treatment. Chest 2004; 125:27–37.
73. Hernan MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, Jick H. Cigarette smoking and the progression of multiple sclerosis. Brain 2005; 128:1461–5.
74. Di Pauli F, Reindl M, Ehling R, et al. Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Mult Scler 2008; 14:1026–30.
75. Pittas F, Ponsonby AL, Van Der Mei IA, et al. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. J Neurol 2009; 256:577–85.
76. Sundstrom P, Nystrom L. Smoking worsens the prognosis in multiple sclerosis. Mult Scler 2008; 14:1031–5.
77. Koch M, van Harten A, Uyttenboogaart M, De Keyser J. Cigarette smoking and progression in multiple sclerosis. Neurology 2007; 69:1515–20.
78. D’hooghe MB, Nagels G. Smoking behavior and multiple sclerosis severity. Mult Scler 2005; 11:S27.
79. Healy BC, Ali EN, Guttmann CRG, et al. Smoking and disease progression in multiple sclerosis. Arch Neurol 2009; 66:858–64.
80. Zivadinov R, Weinstock-Guttman B, Hashmi K, et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology 2009; 73:504–10.
81. Sena A, Couderc R, Ferret-Sena V, et al. Apolipoprotein E polymorphism interacts with cigarette smoking in progression of multiple sclerosis. Eur J Neurol 2009; 16:832–7.
82. Cantorna MT. Vitamin D and multiple sclerosis: an update. Nutr Rev 2008; 66:S135–8.
83. Burton JM, Kimball S, Vieth R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010; 74:1852–9.
84. Ascherio A, Munch M. Epstein–Barr virus and multiple sclerosis. Epidemiology 2000; 11:220–4.
85. Marrie RA, Wolfson C. Multiple sclerosis and Epstein–Barr virus: a review. Canadian Journal of Infectious Diseases 2002; 13:111–18.
86. Jager PLD, Simon KC, Munger KL, Rioux JD, Hafler DA, Ascherio A. Integrating risk factors: HLA-DRB1*1501 and Epstein–Barr virus in multiple sclerosis. Neurology 2008; 70:1113–18.